can ultram cause insomnia
Comparative Table for Ultram Prices
Weight loss drugs combined with a regular workout and a low-calorie diet may produce significant weight loss for obese people. The effect of weight loss drugs is to make people feel fuller after eating a small portion of food. These drugs are recommended for obese people only and should be taken only under medical supervision. The FDA approved appetite-suppressant medications such as phentermine and sibutramine for obese people who want to lose weight. Appetite-suppressants decrease the appetite by impacting the brain chemicals that control it. For instance, Orlistat, is a lipase inhibitor that blocks the breaking down of dietary fat. When this happens, the body takes in fewer calories.
Next partWhat are Sleeping pills?
Sleeping pills are sedatives that depress the central nervous system and cause the body to relax. They have a tranquillizing effect and cause the person feel less anxious. Sleeping pills are also called downers, tranquillizers, depressants, anxiolytics, soporifics or sedative hypnotics. Who should take sleeping pills?
Sleeping pills should not be taken without prescription, as they can be addictive and dangerous to the health. Sleeping pills are generally prescribed for persons with anxiety problems. However, they are also used to help people with chronic insomnia, sleep. The sleeping pill strengthens the sleeping drive and induces sleep. What is the action of the sleeping pill on the human system?
Most people sleep normally because the pineal gland secretes a hormone called melatonin as darkness sets in, and this slows down the body mechanisms and induces the need for sleep.
FLEMINGTON, N. J, -- NovaDel Pharma Inc.(AMEX: NVD) today announced that the U. S. Food and Drug Administration (FDA) has requested an extension of up to 3 months on the Prescription Drug User Fee Act (PDUFA) deadline in order to complete the review of the Company's Zolpimist (zolpidem tartrate) Oral Spray for the short-term treatment of insomnia. Based on the original PDUFA date for Zolpimist, the FDA will reply on or before December 19, 2008."We believe we have submitted a high quality 505(b)(2) application for Zolpimist and will continue to work with the FDA throughout the remaining review process," commented Steven Ratoff, M. D., Chairman of the Board and Interim CEO of NovaDel. Related Results
Zolpidem tartrate and somnambulismHepatotoxicity associated with zolpidem treatmentEffect of zolpidem on driving abilityIntermittent zolpidem dosing works for insomniaDrivers safe when proper zolpidem regimen is followed
NovaDel submitted its Zolpimist application using the FDA's 505(b)(2) process based on bioequivalence data from two randomized, open-label, dose-ranging studies comparing Zolpimist with Ambien([R]) tablets in young and elderly healthy volunteers.